IONM stock down 99.99% on 04 Feb 2026 (market closed): what traders should watch

IONM stock opened a sharp collapse on 04 Feb 2026 and finished the market closed session at $0.0005, down 99.99% from the prior close of $4.20. The drop erased nearly all market value and left trading volumes at 281 shares, signalling a company-specific liquidity and pricing event. Investors should view this move as an extraordinary loss of value on the NASDAQ in the United States and tie it to balance sheet stress, low average trading interest, and potential corporate actions that drove the price swing.

IONM stock price action at market close

Assure Holdings Corp. (IONM) finished the session on NASDAQ in the United States at $0.0005, a -99.99% intraday change from the previous close of $4.20. Volume was 281 shares versus an average volume of 223, and market cap fell to about $1,567.00. This price is below the 50-day average of $0.0043 and far under the 200-day average of $0.03349.

What likely triggered the collapse and market signals

There is no single publicized earnings or regulatory announcement tied to this intraday move; the price action appears company-specific and illiquid. The steep fall with low volume suggests either a technical market event, a large correction after a thinly traded post-split float change, or reporting that eroded investor confidence. Market charting services captured this move; see the trading history on MarketBeat.

Financials and valuation snapshot for Assure Holdings Corp.

Assure Holdings Corp. operates in Healthcare, Medical – Care Facilities, with about 95 full time employees and US operations across multiple states. Recent key metrics show EPS -369.70, price/sales 0.01, enterprise value $14,683,567.00, and current ratio 0.30, highlighting liquidity pressure and negative profitability. The company’s year high was $0.5488 and year low $0.0001, showing extreme historical volatility.

Meyka AI rates IONM with a score out of 100 and technical outlook

Meyka AI rates IONM with a score out of 100: 61.06 / 100, Grade B — Suggestion: HOLD. This grade factors in S&P 500 benchmark comparison, sector and industry performance, financial growth, key metrics, forecast signals, and analyst consensus. Technical indicators show RSI 40.09, ADX 77.99 (strong trend), and CCI 155.56, signalling a sharp directional move but mixed momentum. Traders should treat the technical picture as volatile and driven by microcap liquidity.

Price targets, Meyka AI forecast and risk-reward for IONM stock

Meyka AI’s forecast model projects a quarterly figure of $6.58, which, compared with the $0.0005 close, implies an extreme upside scenario. Conservatively, recovery price targets to watch could be $0.01 (implied upside ~1,900%) and $0.05 (implied upside ~9,900%). These targets are scenario-based and do not reflect analyst consensus, which is currently unavailable. Forecasts are model-based projections and not guarantees.

Final Thoughts

IONM stock’s 99.99% decline to $0.0005 on 04 Feb 2026 (market closed) is a textbook microcap liquidity collapse rather than a standard market drawdown for larger healthcare peers on NASDAQ in the United States. The company shows weak liquidity metrics (current ratio 0.30), negative EPS -369.70, and a tiny market cap of roughly $1,567.00, so any bounce would require material corporate news or restructuring. Meyka AI’s model projects a quarterly figure of $6.58, an aggressive scenario implying roughly 1,315,900% upside versus the current price; that projection is highly model-dependent and unlikely without extraordinary fundamental change. For practical planning, monitor trading volume, SEC filings, and corporate disclosures before treating IONM as a recovery play. This analysis is informational; Meyka AI is an AI-powered market analysis platform and not a financial advisor. Forecasts are model-based projections and not guarantees.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.